It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Nader Kabbani, who led the launch of Amazon Pharmacy and the acquisition of PillPack, will take the chief operating officer ...

But they're selling off shares of Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the latter of which is a Hims & Hers partner now. As of 11:20 a.m. ET, Hims & Hers stock is surging to 11.2% ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...